Synthesis of cycloruthenated compounds as potential anticancer agents
Fiche publication
Date publication
juillet 2007
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GAIDDON Christian, Dr LOEFFLER Jean-Philippe
Tous les auteurs :
Leyva L, Sirlin C, Rubio L, Franco C, Le Lagadec R, Spencer J, Bischoff P, Gaiddon C, Loeffler JP, Pfeffer M
Lien Pubmed
Résumé
A library of 19 cycloruthenated derivatives is constructed by making use of the well-known cyclometalation reaction. Their geometries are modified in a straightforward manner by addition of either mono- or bidentate ligands, such as bipyridine, phenanthroline, 1,2-bis(diphenylphosphanyl)ethane, dimethylphenylphosphane, triphenylphosphane, and 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (PTA) ligands, to cationic cycloruthenated centers. The antitumor properties of the compounds thus obtained are investigated in order to compare them with recently reported ruthenium complexes and cisplatin. IC50 values against mammalian cells (A-172, HCT-116, and RDM-4) are determined for the library compounds and some of them, such as those derived from orthoruthenated phenylpyridine and a bidentate N,N ligand, display activity of the same order of magnitude as cisplatin. ((c) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinhem, Germany, 2007).
Référence
Eur J Inorg Chem. 2007 Jul;19:3055-66